Indian firm seeks EUA in PH for its Covid-19 vaccine Covaxin | Inquirer News

Indian firm seeks EUA in PH for its Covid-19 vaccine Covaxin

/ 01:02 PM January 21, 2021
India vaccine

FILE PHOTO: A healthcare worker fills a syringe with a dose of Bharat Biotech’s Covid-19 vaccine called Covaxin, during the coronavirus disease vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi

MANILA, Philippines — India-based firm Bharat Biotech has applied for emergency use authorization (EUA) for its Covid-19 vaccine Covaxin, the Food and Drug Administration (FDA) said Thursday.

“They submitted an application this morning and pre-evaluation is going on,” FDA Director-General Eric Domingo told in a text message.


Securing an EUA will allow a new vaccine to be administered in the country.

Other companies seeking EUA approval before the Philippine regulators are British firm AstraZeneca, Russian company Gamaleya Research Institute and Chinese drug maker Sinovac Biotech.


So far, only US pharmaceutical giant Pfizer has secured the FDA clearance for its vaccine’s use in the Philippines.


For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Covaxin, COVID-19, pandemic, Philippines
For feedback, complaints, or inquiries, contact us.

© Copyright 1997-2021 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.